AstraZeneca inked a five-year research deal with Harvard Stem Cell Institute (HSCI) for new treatments for diabetes. The company announced today that it has entered into a five-year research collaboration with HSCI to adapt a technique that creates human beta cells from stem cells for use in screens for AstraZeneca’s …